News
Article
Author(s):
The top news stories in medicine today.
The U.S. Food and Drug Administration has approved CT-152 (Rejoyn), the first digital therapeutic to treat major depressive disorder for adults aged 22 years or older and taking antidepressants. The six-week program enhances cognitive control of emotions through therapy and training, according to the developers.
Physicians are smart people. Isn’t it time they had smart stethoscopes? This article explains how stethoscope technology is moving from analog to digital for the 21st century.
If you’ve ever tried to pick winners in the NCAA’s March Madness college basketball tournament, you’re not alone. If you’ve ever thought a pharmaceutical name sounds like it should be a word for, say, an Italian village, a bizarre Pac-Man sequel, or a Premier League footballer, you’re also not alone. Here’s how Fierce Pharma created a challenge to pick the best drug name in 2024. (And if your bracket is busted, no worries, you’re not alone.)